Regeneron Pharmaceuticals, Inc. (REGN) Tops Q4 EPS by 36c

Article Related Press Releases (1) Stock Quotes (1) Comments (0)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q4 EPS of $1.47, $0.36 better than the analyst estimate of $1.11. Revenue for the quarter came in at $415 million versus the consensus estimate of $392.64 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Elan Corp (ELN) Could Be Worth $19 in a Takeout - Jefferies
• PVH Corp. (PVH) Tops Q1 EPS by 56c; Issues Q2 EPS, Revs Outlook
• John Wiley (JW-A) Misses Q4 EPS by 9c; Names New CFO; Updates on Restructuring

Create E-mail Alert Related Categories

Earnings

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?